Efficacy of xihuangwan combined with PP regimen in treatment of non-small cell lung cancer with phlegm and stasis interconnection
Lu Jia-wei
Li Jin-hong
Cheng Guang
Liu Di
Ma Zhi-bin
Yang Chen-rui
Liu Zeng
Liu Fei
Li Bo-yao
Abstract：Objective To observe the clinical efficacy of xihuangwan combined with PP regimen(pemetrexed+cispla-tin)in the treatment of non-small cell lung cancer(NSCLC)with phlegm and stasis interconnection and investigate its safety.Methods Eighty-seven patients with non-small cell lung cancer of the phlegm and stasis interconnection type admitted to Cang-zhou Hospital of Integrated Traditional Chinese and Western Medicine from January 2022 to June 2024 were selected and randomly divided into 2 groups.The 43 patients in the control group were given PP regimen chemotherapy,and those 44 patients in the study group were given xihuangwan oral treatment on the basis of the regimen in the control group.The clinical efficacy,TCM evidence points,serum tumour marker levels,immune function levels and the occurrence of adverse reactions were compared between the two groups.Results The objective remission rate and disease control rate of the study group were 52.27%(23/44)and 84.09%(37/44),respectively,which were higher than those of the control(30.23%(13/43)and 60.47%(26/43))(χ2=4.355,6.077,P<0.05).They were lower in the study group((6.89±1.24)points)than in the control((8.67±1.45)points)(t=6.159,P<0.05).Serum CEA,NSE,and CY-FRA21-1 levels in the study group after treatment were(23.34±3.56)ng·L-1,(25.12±3.76)μg·L-1,(3.23±0.48)ng·L-1,respectively,and they were lower than those of the control((27.45±3.78)ng·L-1,(28.90±4.28)μg·L-1,(3.75±0.53)ng·L-1)(t=5.222,4.379,4.799,all P<0.05).CD3+,CD4+and CD4+/CD8+levels of the study group were(61.45±4.12)%,(39.46±2.15)%,(1.54±0.23),respective-ly,which were higher than those of the control((56.32±4.47)%,(36.26±2.48)%,(1.27±0.25),respectively)(t=5.568,6.435,5.224,P<0.05).The incidence of adverse reactions such as nausea and vomiting,thrombocytopenia,leucopenia and hepatic and renal im-pairment of the study group were lower than those of the control(χ2=7.228,4.506,5.213,3.941,all P<0.05).Conclusion The efficacy of xihuangwan combined with PP regimen in the treatment of phlegm-stasis-mutual-conjugation type of non-small cell lung cancer is remarkable since it can effectively improve the patients'TCM symptoms,reduce the level of tumour markers,improve the patients'immune function and reduce the occurrence of adverse reactions.
Keywords：Non-small cell lung cancerPhlegm and stasis interconnected typeXihuangwanTumor markerImmune functionClinical efficacy
Publication Date：2025-02-24
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 111-115 )